AI-Designed TNIK Inhibitor Rentosertib Shifts Proteomic Aging Clocks in IPF Trial, Advancing Dual-Purpose Geroprotective Research

A peer-reviewed analysis published in Nature Biotechnology on September 7, 2026, reports that rentosertib (formerly ISM001-055), an AI-designed small-molecule inhibitor of TNIK developed by Insilico Medicine, produced consistent reductions in predicted biological age across six independent proteomic aging clocks in a Phase IIa trial for idiopathic pulmonary fibrosis (IPF). The study analyzed longitudinal serum proteome data from 42 patients (out of 71 enrolled), measuring 2,841 proteins via Olink panels and applying clocks including ProtAge, OrganAge (chronological and mortality variants), PAC, ipfP3GPT, and PAOPAC—developed by independent teams at institutions such as Harvard, Oxford, Peking University, and Insilico itself. All six clocks indicated lower predicted biological age in treated arms versus placebo, with peak effects around week 4 (roughly 2.7–3.5 years reversal on chronological clocks in the 30 mg BID or 60 mg QD arms, and up to 6 years on select models). Placebo groups showed minimal change or slight increases. Pathway analyses suggested shifts in senescence and metabolic processes alongside anti-fibrotic effects, though the authors caution that proteomic clocks cannot fully disentangle aging-specific from disease-specific changes. This builds on earlier Phase IIa efficacy data published in Nature Medicine (June 2025), where the 60 mg QD arm showed a mean FVC improvement of +98.4 mL versus -20.3 mL on placebo. Rentosertib targets TNIK, identified via Insilico’s PandaOmics platform as linked to six hallmarks of aging and fibrosis; the molecule was generated using Chemistry42. The drug has advanced to a randomized Phase III trial (GENESIS-IPF-3) enrolling 320 patients over 52 weeks, with first patients dosed in September 2026. Commentators including Nobel laureate Michael Levitt have noted the convergence across independent models as compelling, while Insilico’s Alex Zhavoronkov highlighted potential economic implications of extending healthy lifespan. The work represents the first reported clinical integration of multiple proteomic aging clocks in a drug trial and validates AI-driven discovery for age-related conditions, though larger, longer studies are needed to confirm any true geroprotective impact beyond IPF symptom management.